NASDAQ · PRE
Prenetics Global Limited
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
Loading market information…
NASDAQ · NLSP · USD
Stock price, earnings
Quote as of Dec 12, 2025, 02:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NLS Pharmaceutics AG’s quoted price sits in the lower half of its reported 52-week range, 93.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow NLS Pharmaceutics AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD. Established in 2015, the company maintains its headquarters in Zurich, Switzerland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:49 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$29.46-$0.89 (-2.93%)
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
$3.31-$0.19 (-5.43%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.35% below the high.
$0.85-$0.09 (-9.66%)
Celularity Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.69% below the high.
$0.37-$0.02 (-5.95%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$5.78+$0.12 (+2.12%)
Nuwellis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.63% below the high.
$0.01$0.00 (0.0%)
CERo Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.76% below the high.
